Clinical Characteristics and Management of Patients with Heart Failure in Egypt: Real-world Insights from iCaReMe Global Registry

There is a paucity of data regarding the clinical characteristics, management practices and burden of disease in patients (pts) with HF, assessment of which may help in understanding the treatment gaps and facilitating the best possible HF care.

The HF cohort of iCaReMe (NCT03549754) aims to describe the clinical profile, treatment patterns, and comorbidities in pts with HF.

This prospective, investigator-led, multinational, cloud-based, observational registry enrolled eligible adults with HF, T2D, HTN and/or CKD during their routine clinical care from Feb 2018 to Dec 2022.

A descriptive analysis of baseline clinical characteristics and treatment patterns of the Egypt-HF cohort is presented.

1400 patients were enrolled in the Egyptian cohort of this study from mainly from the National Heart Institute.

This cohort enrolled 1111 pts with HF (mean±SD age 56.8±11.8 years); 60.9% were males. Overall, 66.6% (740) pts had HFrEF (≤40%), 14.8% (164) had HFmrEF (41%-49%), and 18.6% (207) had HFpEF (≥50%). The majority (68.0%) had NYHA class II HF. Only 1 pt had a BNP report (150 pg/mL) and 18 pts had proBNP levels (mean±SD, 354.4±189.6 pg/mL). Almost half pts reported a history of coronary artery disease (48.9%) and T2D (48.0%). About 20.2% pts reported a history of hospitalization.

The Egyptian cohort of iCaReMe registry results emphasize a high HF burden in Egypt with more than two-thirds having a reduced EF, about half of them had associated comorbidities and the number 1 co-morbidity in overall HF and HFrEF is CAD, while in HFmrEF it is HTN and in HFpEF it is T2D while the mean EF in HFpEF is 60.3%, the mean NT-Pro BNP in HF is 395.5 ng/L.